Interpretation of the Essential Updates in 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure

doi:10.12114/j.issn.1007-9572.2022.0288

Chinese General Practice ›› 2022, Vol. 25 ›› Issue (17): 2051-2054.DOI: 10.12114/j.issn.1007-9572.2022.0288

Special Issue: 指南/共识最新文章合辑；心力衰竭最新文章合辑；心血管最新文章合辑

• Guideline & New Evidence • Next Articles

Interpretation of the Essential Updates in 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure

Hebei General Hospital, Shijiazhuang 050051, China

Received:2022-04-11 Revised:2022-04-13 Published:2022-04-15 Online:2022-04-15
About author:
GUO Y F. Interpretation of the essential updates in 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure[J]. Chinese General Practice, 2022, 25 (17) : 2051-2054.

2022年美国心力衰竭管理指南更新要点解读

050051　河北省石家庄市，河北省人民医院

作者简介:

专家介绍：郭艺芳，主任医师，教授，博士研究生导师，现任河北省人民医院副院长。兼任中国医师协会高血压专业委员会副主任委员、中国老年医学学会高血压分会副会长、中华医学会老年医学分会委员、中国高血压联盟常务理事、河北省医学会老年医学分会主任委员、河北省医师协会高血压专业医师分会主任委员、河北省医学会医学工程分会主任委员等，以及《中华内科杂志》《中华老年医学杂志》《中华心血管病杂志》《中国全科医学》《中华全科医师杂志》编委，《中华高血压杂志》与《中国心血管杂志》常务编委。享受国务院特殊津贴。

郭艺芳. 2022年美国心力衰竭管理指南更新要点解读[J].中国全科医学，2022，25（17）：2051-2054. [www.chinagp.net]

Abstract

Abstract:

The American Heart Association (AHA) , American College of Cardiology (ACC) and Heart Failure Society of America (HFSA) jointly released the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (hereinafter referred to as the 2022 Guideline) . In the light of the latest evidence, the essentials updated in the 2022 Guideline encompass the prevention, stages, classification, drug treatment and device-based treatment of heart failure. The 2022 Guideline is content-enriched, evidence-based, practical, and easily operable, which may greatly contribute to clinical practice in China. In response to the most concerns of clinicians, we overviewed and discussed the updates in stages, classification and drug treatment of heart failure in the new guideline.

Key words: Heart failure, Heart failure with reduced ejection fraction, Heart failure with preserved ejection fraction, Heart failure with mildly reduced ejection fraction, Heart failure with improved ejection fraction, SGLT2 inhibitors, Guideline

摘要：

美国心脏协会（AHA）、美国心脏病学会（ACC）与美国心力衰竭学会（HFSA）联合颁布了2022年美国心力衰竭管理指南。该指南结合最新研究证据对心力衰竭的预防、分期、分型、药物治疗以及器械治疗等方面进行了修订，其内容丰富，遵循证据，注重实践，可操作性好，对于我国临床实践具有很好的借鉴价值。本文针对临床医生最为关心的心力衰竭分期、分型与药物治疗的更新要点进行介绍和简要讨论。

关键词: 心力衰竭, 射血分数降低的心力衰竭, 射血分数保留的心力衰竭, 射血分数轻度降低的心力衰竭, 射血分数改善的心力衰竭, 钠葡萄糖共转运蛋白-2抑制剂, 指南

Yifang GUO. Interpretation of the Essential Updates in 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure[J]. Chinese General Practice, 2022, 25(17): 2051-2054. DOI: 10.12114/j.issn.1007-9572.2022.0288.
郭艺芳. 2022年美国心力衰竭管理指南更新要点解读[J]. 中国全科医学, 2022, 25(17): 2051-2054. DOI: 10.12114/j.issn.1007-9572.2022.0288.

References 6

[1]	HEIDENREICH P A，BOZKURT B，AGUILAR D，et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure：executive summary：a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol，2022，24：S0735-1097（21）08394-7. DOI：10.1016/j.jacc.2021.12.011.
[2]	YANCY CW，JESSUP M，BOZKURT B，et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure：a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. Circulation，2017，136（6）：e137-161. DOI：10.1161/CIR.0000000000000509.
[3]	MCMURRAY J J V，SOLOMON S D，INZUCCHI S E，et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med，2019，381（21）：1995-2008. DOI：10.1056/NEJMoa1911303.
[4]	PACKER M，ANKER S D，BUTLER J，et al. Cardiovascular and renal outcomes with empagliflozin in heart failure[J]. N Engl J Med，2020，383（15）：1413-1424. DOI：10.1056/NEJMoa2022190.
[5]	SOLOMON S D，MCMURRAY J J V，ANAND I S，et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J]. N Engl J Med，2019，381（17）：1609-1620. DOI：10.1056/NEJMoa1908655.
[6]	ANKER S D，BUTLER J，FILIPPATOS G，et al. Empagliflozin in heart failure with a preserved ejection fraction[J]. N Engl J Med，2021，385（16）：1451-1461. DOI：10.1056/NEJMoa2107038.

[1]	MA Shuangshuang, XING Yanjiang, ZHANG Jiawei, WANG Jing. Research Progress on Cardiac Energy Metabolic Changes in Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2025, 28(30): 3831-3840.
[2]	LIU Zhenyu, WEI Yunpeng, WANG Jiangmin, XING Yan. Causal Association Study between Sleep Duration and Heart Failure [J]. Chinese General Practice, 2025, 28(27): 3441-3446.
[3]	CUI Yiyuan, YAN Yijing, WANG Ying, MENG Xiangju, ZHANG Qinglin, LIU Lixing, LI Sicong, FENG Li, The Working Group for the Clinical Practice Guideline for the Cancer-related Fatigue with Integrated Traditional Chinese and Western Medicine. Clinical Practice Guideline for the Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Cancer-related Fatigue [J]. Chinese General Practice, 2025, 28(27): 3345-3358.
[4]	ZHI Congcong, LI Xue, CHENG Yicheng, WANG Xiaolong, ZHENG Lihua. Guidelines for Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Hemorrhoids (2025 Edition) [J]. Chinese General Practice, 2025, 28(26): 3217-3228.
[5]	LIU Wenjie, SUN Huang, LUO Wei, CHEN Xuan, PENG Yunzhu, LI Ruijie, MA Mier. Wearable Acoustic-electrocardiographic Remote Monitoring Device for Heart Failure [J]. Chinese General Practice, 2025, 28(25): 3104-3109.
[6]	HAN Bing, DU Shuzhen, MENG Xiaoxue, ZHANG Lu, CHEN Zixian, TENG Fengling. Plasma Periostin Levels Correlated with Myocardial Fibrosis in Patients with Heart Failure with Different Ejection Fraction [J]. Chinese General Practice, 2025, 28(24): 2979-2984.
[7]	YANG Chen, CHEN Tong, ZHANG Lifang, ZHANG Hongxu, LI Pengfei, ZHANG Xuejuan. Prognostic Impact of Dapagliflozin in Elderly Breast Cancer Survivors with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes [J]. Chinese General Practice, 2025, 28(24): 3053-3058.
[8]	DONG Haocheng, HAO Xiao, AN Dong, LI Haohan, LI Shuren. Research Progress of Heart Failure with Supra-normal Ejection Fraction [J]. Chinese General Practice, 2025, 28(21): 2692-2696.
[9]	YANG Jiang, LI Jiansheng, CHEN Yaolong, LIU Huiguo, WANG Jianxin, YU Jiajie, LI Huiru, XIAO Qionghua, XIE Yang, LI Suyun, WANG Minghang. Guideline on Treating Adult Community-acquired Pneumonia with Chinese Patent Medicines (2025 Edition) [J]. Chinese General Practice, 2025, 28(20): 2464-2480.
[10]	CAO Qinhan, ZHUO Xiao, XIA Yuhan, CHE Yangxi, CHEN Min. Interpretation of Updated NCCN Clinical Guidelines for Rectal Cancer (2024.V1/V2) [J]. Chinese General Practice, 2025, 28(17): 2070-2074.
[11]	HE Ting, LI Jia, TAN Wenbin. Research Progress of Circulatory System Diseases and Secondary Osteoporosis [J]. Chinese General Practice, 2025, 28(17): 2101-2112.
[12]	XIA Yuhan, ZHUO Xiao, CAO Qinhan, LIAO Xingyu, LUO Guoliang, TANG Taichun, CHEN Min. Interpretation of the Updated NCCN Clinical Practice Guidelines for Colon Cancer (2024.V4) [J]. Chinese General Practice, 2025, 28(14): 1689-1693.
[13]	MA Guifen, ZHANG Qian, SUN Jing. Interpretation of the Key Updates in the Latest Version of 2024 NCCN Clinical Practice Guidelines for Gastric Cancer [J]. Chinese General Practice, 2025, 28(14): 1681-1688.
[14]	HUANG Chuanying, LIAO Xiaoyang, YANG Rong, LI Dongze, ZHANG Peng, JIA Yu, LIU Lidi. Interpretation of the Clinical Statement for Management of Female Cardiac Emergencies in 2024 [J]. Chinese General Practice, 2025, 28(12): 1427-1432.
[15]	Chinese Academy Society of Sleep Medicine, Chinese Medical Doctor Association, Sleep Medicine Group, China Neurologist Association. Chinese Guideline for Diagnosis and Treatment of Co-morbid Insomnia and Obstructive Sleep Apnea (2024) [J]. Chinese General Practice, 2025, 28(11): 1289-1303.

Interpretation of the Essential Updates in 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure

2022年美国心力衰竭管理指南更新要点解读

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References 6

Related Articles 15

Recommended Articles

Metrics

Comments